DOI: 10.6084/m9.figshare.6916541
title: Additional file 1: of eQTL discovery and their association with severe equine asthma in European Warmblood horses

description: Figure S1. Minimum D-statistics determine mean read count cutoffs. Figure S2. PCA plots of normalized variance stabilized RNAseq counts after KS test filter. Figure S3. PCA plots of 1,056,195 SNP genotypes and colored by cohort. Figure S4. Matrix eQTL histograms and QQ-plots for all p-values for all cis and trans eQTL analyses using tag SNPs for the MCK1 treatment. Figure S5. Low confidence cis eQTLs. Figure S6. Joint modeling with eQTLBMA with possible overestimation of shared eQTLs across all PBMC treatments. Figure S7. Distance between eSNPs with the lowest FDR values per gene is small. Figure S8.. Enrichment of SNPs in trans regulatory hotspots genome wide. Figure S9. GWAS for RAO. Figure S10. Loss of DEXI gene expression regulation in HDE. Figure S11. Cis trans eQTL plot for all eQTLs for treatment HDE9. Table S1. High confidence additive linear cis eQTLs from the MCK treatment. Table S2. Low confidence additive linear cis eQTLs from the MCK treatment. Table S3. High confidence additive linear trans eQTLs from the MCK treatment. Table S4. Low confidence additive linear trans eQTLs from the MCK treatment. Table S5. High confidence additive linear cis eQTLs from the LPS treatment. Table S6. Low confidence additive linear cis eQTLs from the LPS treatment. Table S7. High confidence additive linear trans eQTLs from the LPS treatment. Table S8. Low confidence additive linear trans eQTLs from the LPS treatment. Table S9. High confidence additive linear cis eQTLs from the RCA treatment. Table S10. Low confidence additive linear cis eQTLs from the RCA treatment. Table S11. High confidence additive linear trans eQTLs from the RCA treatment. The eQTLs reported are limited to one eQTL per gene, representing the eSNP with the lowest FDR value for each gene. Table S12. Low confidence additive linear trans eQTLs from the RCA treatment. Table S13. High confidence additive linear cis eQTLs from the HDE treatment. Table S14. Low confidence additive linear cis eQTLs from the HDE treatment. Table S15. High confidence additive linear trans eQTLs from the HDE treatment. Table S16. Low confidence additive linear trans eQTLs from the HDE treatment. Table S17. Two proportion z-test calculation. Table S18. 4157 significant eQTLs discovered with eQTLBMA. Table S19. Trans eQTL results for the trans regulatory hotspot on chromosome 11 (SNP MNEc.2.11.60892596.PC). Table S20. Trans eQTL results for the trans regulatory hotspot on chromosome 13 (SNP MNEc.2.13.18333037.PC). Table S21. Panther gene enrichment GO process results for genes regulated by the trans regulatory hotpot on chromosome 11 (MNEc.2.11.60892596.PC). Table S22. Panther gene enrichment GO process results for genes regulated by the trans regulatory hotpot on chromosome 13 (MNEc.2.13.18333037.PC). Table S23. GWAS results. Table S24. All significant cis eQTLs for the MCK treatment. Table S25. All significant cis eQTLs for the LPS treatment. Table S26. All significant cis eQTLs for the RCA treatment. Table S27. All significant cis eQTLs for the HDE treatment. Table S28. Linkage disequilibrium and allele frequencies between RAO associated SNPs on chromosome 13 positions 32,843,309 â 33,502,488. Table S29. Sample information for 82 individuals used in eQTL analyses. Table S30. Sample information for all 379 individuals. (ZIP 51963 kb)